Evidence map›Paper›PMID 41627880›Full record

ReviewJournal of the National Cancer Institute2026

Driving progress in recurrent and metastatic head and neck cancer: the NRG Oncology perspective.

Mercedes Herrera, Matthew Ward, Glenn J Hanna, Sue S Yom, Dwight Heron, Anna Spreafico

Abstract readReview
In one paragraph

Review in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Mercedes HerreraDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-8553-3919
Matthew WardLevine Cancer Institute, Atrium Health, Charlotte, NC, United States.ORCID 0000-0002-8423-890X
Glenn J HannaDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-9969-2523
Sue S YomDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, United States.ORCID 0000-0002-0779-7476
Dwight HeronDepartment of Radiation Oncology, Bon Secours Mercy Health System, Youngstown, OH, United States.ORCID 0000-0001-6282-1806
Anna SpreaficoDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-3034-3042

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
National Cancer Institute of the US National Institutes of Health under U10CA180868NCI NIH HHS U10 CA180868NIH HHS
6 · The paper itself

Abstract

Head and neck cancers represent a diverse group of malignancies with substantial heterogeneity in biology and prognosis for which management of advanced-stage disease remains a formidable challenge. Although the incorporation of immune checkpoint inhibitors has led the way to a new era of treatment possibilities, the current state of the science calls for further innovation and a nuanced approach to clinical trial design to address several unmet needs. This article from the NRG Oncology Recurrent/Metastatic Head and Neck Working Group aimed to critically identify gaps in clinical practice and the scientific literature and to propose actionable recommendations for future research in the framework of recurrent or metastatic squamous cell carcinoma of the head and neck.

Indexed as

Head and Neck NeoplasmsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckHumansImmune Checkpoint InhibitorsNeoplasm MetastasisImmune Checkpoint Inhibitors

Identifiers

PMID41627880
PMCPMC13101959

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.